摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-苯甲基-1H-吡唑-4-硼酸 | 852362-22-2

中文名称
1-苯甲基-1H-吡唑-4-硼酸
中文别名
1-苄基-1H-吡唑-4-硼酸;1-苯甲基-1H-吡唑-4-硼酸,95;1-苯甲基-1H-吡唑-4-硼酸,95%
英文名称
(1-benzyl-1H-pyrazol-4-yl)boronic acid
英文别名
1-Benzyl-1H-pyrazole-4-boronic acid;(1-benzylpyrazol-4-yl)boronic acid
1-苯甲基-1H-吡唑-4-硼酸化学式
CAS
852362-22-2
化学式
C10H11BN2O2
mdl
MFCD04038760
分子量
202.021
InChiKey
JXNAIAOHYPDQQC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    76-81℃
  • 沸点:
    438.4±47.0 °C(Predicted)
  • 密度:
    1.17
  • 稳定性/保质期:
    按规定使用和贮存的情况下,该物质不会分解,并且能够避免与氧化物接触。

计算性质

  • 辛醇/水分配系数(LogP):
    1.69
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    58.3
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 海关编码:
    2933199090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    请将药品存放在密闭、阴凉、干燥的地方。

SDS

SDS:b86ad9980e467f4e9ba956c40504cf6c
查看
Material Safety Data Sheet

Section 1. Identification of the substance
1-Benzyl-1H-pyrazole-4-boronic acid
Product Name:
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

Section 3. Composition/information on ingredients.
1-Benzyl-1H-pyrazole-4-boronic acid
Ingredient name:
CAS number: 852362-22-2

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H11BN2O2
Molecular weight: 202.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-苯甲基-1H-吡唑-4-硼酸N-碘代丁二酰亚胺potassium acetate 作用下, 以 乙腈 为溶剂, 反应 4.0h, 以87%的产率得到1-苄基-4-碘-1H-吡唑
    参考文献:
    名称:
    使用亲电子卤素的铜催化的芳基硼酸卤代硼化的机理:放射性标记应用的碱催化的碘脱硼化的发展。
    摘要:
    报道了使用亲电子卤素试剂对铜催化的芳基硼酸卤代硼烷化反应机理的研究。提供的证据表明这是通过硼酸酯驱动的ipso取代途径发生的,并且这些过程的运行不需要Cu:一般的Lewis碱催化是可行的。这进而允许合理开发通用,简单且有效的碱催化卤代硼烷,该卤代硼烷适合制备125 I标记的SPECT应用产品。
    DOI:
    10.1021/acs.orglett.9b00942
点击查看最新优质反应信息

文献信息

  • [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2014164467A1
    公开(公告)日:2014-10-09
    The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    该披露通常涉及到I式化合物,包括用于治疗人类免疫缺陷病毒(HIV)感染的组合物和方法。该披露提供了HIV的新型抑制剂,含有这些化合物的药物组合物,以及在治疗HIV感染中使用这些化合物的方法。
  • Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors
    作者:Areum Park、Jieon Hwang、Joo-Youn Lee、Eun Ji Heo、Yoon-Ju Na、Sein Kang、Kyu-Sung Jeong、Ki Young Kim、Sang Joon Shin、Hyuk Lee
    DOI:10.1016/j.bmcl.2021.128226
    日期:2021.9
    1B inhibitors, 1H-pyrazolo[3,4-b]pyridine derivatives were synthesized. Mostly, 3-aryl-5-arylamino compounds (6) and 3,5-diaryl compounds (8 and 9) were prepared and especially, 3,5-diaryl compound 8 and 9 showed excellent DYRK1B inhibitory enzymatic activities with IC50 Values of 3–287 nM. Among them, 3-(4-hydroxyphenyl), 5-(3,4-dihydroxyphenyl)-1H-pyrazolo[3,4-b]pyridine (8h) exhibited the highest
    作为DYRK1A和1B抑制剂,合成了1H-吡唑并[3,4- b ]吡啶衍生物。主要制备了3-芳基-5-芳基氨基化合物( 6 )和3,5-二芳基化合物( 8和9 ),特别是3,5-二芳基化合物8和9表现出优异的DYRK1B抑制酶活性,IC 50值为3–287 nM。其中,3-(4-羟基苯基)、5-(3,4-二羟基苯基)-1 H-吡唑并[3,4 -b ]吡啶( 8h )表现出最高的抑制酶活性(IC 50 = 3 nM),对 HCT116 结肠癌细胞的细胞增殖抑制活性 (IC 50 = 1.6 µM)。化合物8h在患者来源的结肠癌类器官模型以及 SW480 和 SW620 的 3D 球体测定模型中也具有出色的抑制活性。对接研究支持我们确认化合物8h通过各种氢键相互作用和疏水相互作用与 DYRK1B 结合。
  • Inhibitors of bacterial biofilms and related methods
    申请人:Sequoia Sciences, Inc.
    公开号:US08324264B1
    公开(公告)日:2012-12-04
    Certain multi-cyclic compounds and compositions thereof are useful for reducing or inhibiting the growth of bacterial biofilms and for controlling bacterial biofilm infections. Such compounds and compositions are also useful in methods for reducing or inhibiting the growth of biofilms and for controlling bacterial biofilm infections involving biofilms.
    某些多环化合物及其组合物对于减少或抑制细菌生物膜的生长以及控制细菌生物膜感染是有用的。这样的化合物和组合物在减少或抑制生物膜生长的方法以及控制涉及生物膜的细菌生物膜感染中也是有用的。
  • Ni <i>vs.</i> Pd in Suzuki–Miyaura sp<sup>2</sup>–sp<sup>2</sup> cross-coupling: a head-to-head study in a comparable precatalyst/ligand system
    作者:Matthew J. West、Allan J. B. Watson
    DOI:10.1039/c9ob00561g
    日期:——
    cornerstone method for sp2–sp2 cross-coupling in industry. There has been a concerted effort to enable the use of Ni catalysis as an alternative to Pd in order to mitigate cost and improve sustainability. Despite significant advances, ligand development for Ni-catalyzed Suzuki–Miyaura cross-coupling remains underdeveloped when compared to Pd and, as a consequence, ligands for Ni-catalyzed processes are typically
    Suzuki–Miyaura反应是sp 2 –sp 2的基石方法工业中的交叉耦合。为了降低成本和提高可持续性,已经做出了共同的努力以使得能够使用Ni催化来代替Pd。尽管取得了重大进展,但与Pd相比,Ni催化的Suzuki-Miyaura交叉偶联的配体开发仍不发达,因此,Ni催化过程的配体通常取自Pd舞台。在这项研究中,我们评估了以常见的双齿配体(dppf)为首对首形式使用相似的Ni和Pd预催化剂对联芳偶合的最常见类型的效果,建立了直接替代Pd的实际含义与Ni一起,并从机械角度确定这些观察的潜在起源。
  • Novel inhibitors of bacterial biofilms and related methods
    申请人:Sequoia Sciences, Inc.
    公开号:EP2712863A1
    公开(公告)日:2014-04-02
    Multi-cyclic compounds of chemical structure represented by formula given below and compositions thereof are useful for reducing or inhibiting the growth of bacterial biofilms and for controlling bacterial biofilm infections. Such compounds and compositions are also useful in methods for reducing or inhibiting the growth of biofilms and for controlling bacterial biofilm infections involving biofilms.
    多环化合物,其化学结构由下述公式表示,以及包含它们的组合物,对于减少或抑制细菌生物膜的生长以及控制细菌生物膜感染是有用的。这样的化合物和组合物在减少或抑制生物膜生长的方法以及控制涉及生物膜的细菌生物膜感染中也同样有用。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐